Abstract
PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra®. An inadequate response was defined for this study by patient report indicating that achievement of an erection suitable for vaginal penetration occurred ≤50% of the time while taking 100 mg Viagra®. Erectile responses were assessed by RigiScan™ in healthy subjects in the absence of visual sexual stimulation (VSS) and in ED patients in the presence of VSS. Doses ranging from 0.3 to 10 mg were administered to healthy male subjects, resulting in a statistically significant erectile response at doses greater than 1.0 mg. ED patients were treated with placebo, 4 or 6 mg PT-141 in a crossover design in the presence of VSS. The erectile response induced by PT-141 was statistically significant at both doses. PT-141 was safe and well tolerated in both studies. The erectogenic potential of PT-141, its tolerability profile and its ability to cause significant erections in patients who do not have an adequate response to a PDE5 inhibitor suggest that PT-141 may provide an alternative treatment for ED with a potentially broad patient base.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lue TF . Erectile dysfunction. N Engl J Med 2000; 342: 1802–1813.
Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404.
Porst H et al. The efficacy and tolerability of Vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192–199.
Padma-Nathan H et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2–9.
Padma-Nathan H, Steers WD, Wicker PA . Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Int J Clin Pract 1998; 52: 375–379.
Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426.
McCullough A, Woo K, Telegrafi S, Lepor H . Is sildenafil failure in men after radical retropubic prostatectomy (RRP) due to arterial disease? Penile duplex Doppler findings in 174 men after RRP. Int J Impot Res 2002; 14: 462–465.
Hatzichristou DG . Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002; 14(Suppl 1): S43–S52.
Souverein PC et al. Incidence and determinants of sildenafil (dis) continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14: 259–265.
Andersson K-E, Hedlund P . New directions for erectile dysfunction therapies. Int J Impot Res 2002; 14(Suppl 1): S82–S92.
Wessells H et al. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. Urology 2000; 56: 641–646.
Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann NY Acad Sci 2003; 994: 96–102.
Gantz I et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 1993; 268: 8246–8250.
Gantz I et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 1993; 268: 15174–15179.
Diamond LE et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004; 16: 51–59.
Rosen RC et al. The International Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.
Capelleri JC et al. Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology 1999; 54: 346–351.
Wikberg JE et al. New aspects on the melanocortins and their receptors. Pharmacol Res 2000; 42: 393–420.
Argiolas A, Melis MR, Murgia S, Schioth HB . ACTH-and alpha-MSH-induced grooming, stretching, yawning and penile erection in male rats: site of action in the brain and role of melanocortin receptors. Brain Res Bull 2000; 51: 425–431.
Argiolas A, Melis MR, Gessa GL . Yawning and penile erection: central dopamine–oxytocin–adrenocorticotropin connection. Ann NY Acad Sci 1988; 525: 330–337.
Van der Ploeg LHT, Martin WJ, Howard AD, Nargund RP . A role for the melanocortin 4 receptor in sexual function. Proc Natl Acad Sci USA 2002; 99: 11381–11386.
McKinlay JB . The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000 Oct 12; (Suppl 4): S6–S11.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosen, R., Diamond, L., Earle, D. et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®. Int J Impot Res 16, 135–142 (2004). https://doi.org/10.1038/sj.ijir.3901200
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901200
Keywords
This article is cited by
-
Genetics and erectile dysfunction: leveraging early foundations for new discoveries
International Journal of Impotence Research (2022)
-
Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration
Drugs in R&D (2021)
-
An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction
Nature Reviews Urology (2010)
-
Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction
Nature Reviews Drug Discovery (2008)
-
Clinical applications of centrally acting agents in male sexual dysfunction
International Journal of Impotence Research (2008)